The current situation of cancer morbidity and mortality in the light of the National Cancer Registry, Hungary. Studies on prostatic cancer.
- Clinical Trials Register
- Felfázás specialista
- SITC Exhibitors - SITC
- Subjects must meet all of the following criteria to be enrolled in this study: 1.
- Николь пришлось целых два раза притаиться, пропуская по дороге отряд солдат или рабочих.
- А это наш приятель Арчи.
The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. Treatment strategies for advanced prostate cancer.
Actualities in the medical treatment of metastatic prostate cancer. Novelties in diagnostics and treatment of prostate cancer.
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer GETUG-AFU 15 : a randomised, open-label, phase 3 trial. Lancet Oncol.
J Clin Oncol. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer STAMPEDE : survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Lancet ; — Eur Urol. Ann Oncol. Androgen receptor-mediated processes in castrate-resistant metastatic prostate cancer.
Abiraterone and increased survival in metastatic prostate cancer. Abiraterone in metastatic prostate cancer without previous chemotherapy.
The has a broad clinical and pre-clinical product pipeline. Our differentiated pipeline stands as proof of our ability to identify and address the areas of unmet treatment need and includes three Genmab-created antibodies, out-licensed and developed by partners, that were approved by the U. Food and Drug Administration with breakthrough designations—Daratumumab, Ofatumumab and Teprotumumab www. Our expertise allows the company to provide first-in-class immune-based diagnostic solutions to health care professionals but also execute biomarkers studies and companion diagnostic assay developed in conformity with regulations and in partnership with pharmaceuticals industries.
Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. Abiraterone for prostate cancer not previously treated with hormone therapy.
It is well recognised that this is likely to cause more diabetes and cardiovascular disease. A total of people developed one of the 22 cancers studied over the follow-up period. BMI was associated with 17 out of the 22 specific types of cancer examined. There was some evidence that those with high BMI were at a slightly reduced risk of prostate cancer and premenopausal breast cancer. For example, risk of cancer of the uterus increased substantially at higher body mass index; for other cancers, we saw more modest increases in risk, or no effect at all.
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. Prostate Cancer Prostatic Dis.